The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy

Behavioural Brain Research

Volumn 262, Issue , 2014, Pages 8-13

  Weinhold, Sara Lena ^a   Seeck Hirschner, Mareen ^a   Nowak, Alexander ^a   Hallschmid, Manfred ^b   Göder, Robert ^a   Baier, Paul Christian ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Attention; Hypocretin 1; Intranasal; Narcolepsy; Orexin A; Sleep stability

Indexed keywords

OREXIN A; PLACEBO;

ADULT; ARTICLE; ATTENTION; CATAPLEXY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MORNING DOSAGE; NARCOLEPSY; OUTCOME ASSESSMENT; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SINGLE DRUG DOSE; SLEEP; SLEEP TIME; TREATMENT OUTCOME; WAKEFULNESS;

ATTENTION; HYPOCRETIN-1; INTRANASAL; NARCOLEPSY; OREXIN-A; SLEEP STABILITY;

ADMINISTRATION, INTRANASAL; ADULT; ATTENTION; CATAPLEXY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NARCOLEPSY; NEUROPEPTIDES; SLEEP, REM; WAKEFULNESS;

EID: 84892516058     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.12.045     Document Type: Article

References (53)

1. American Academy of Sleep Medicine International Classification of Sleep Disorders, Second Edition (ICSD-2): Diagnostic and Coding Manual 2005, American Sleep Disorders Association, Rochester, Minnesota.
2. Baker T.L., Guilleminault C., Nino-Murcia G., Dement W.C. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986, 9:232-242.
3. Montplaisir J., Billiard M., Takahashi S., Bell I.R., Guilleminault C., Dement W.C. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:73-89.
4. Plazzi G., Serra L., Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008, 12:109-128.
5. Wittig R., Zorick F., Piccione P., Sicklesteel J., Roth T. Narcolepsy and disturbed nocturnal sleep. Clin Electroencephalogr 1983, 14:130-134.
6. Weinhold S.L., Seeck-Hirschner M., Nowak A., Göder R., Baier P.B. Wake-REM sleep transitions for measuring REM sleep disturbance: comparison between narcolepsy, idiopathic hypersomnia and healthy controls. Sleep Biol Rhythms 2011, 9:172-177.
7. Fulda S., Schulz H. Cognitive dysfunction in sleep disorders. Sleep Med Rev 2001, 5:423-445.
8. Rieger M., Mayer G., Gauggel S. Attention deficits in patients with narcolepsy. Sleep 2003, 26:36-43.
9. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci 1998, 95:322-327.
10. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:691-696.
11. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
12. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
13. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci 1999, 96:10911-10916.
14. Piper D.C., Upton N., Smith M.I., Hunter A.J. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000, 12:726-730.
15. Akanmu M.A., Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res 2005, 1048:138-145.
16. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000, 20:7760-7765.
17. Estabrooke I.V., McCarthy M.T., Ko E., Chou T.C., Chemelli R.M., Yanagisawa M., et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001, 21:1656-1662.
18. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
19. Blouin A.M., Fried I., Wilson C.L., Staba R.J., Behnke E.J., Lamet H.A., et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun 2013, 4:1547.
20. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
21. Gerashchenko D., Kohls M.D., Greco M., Waleh N.S., Salin-Pascual R., Kilduff T.S., et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci 2001, 21:7273-7283.
22. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
23. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci 2004, 101:4649-4654.
24. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
25. Dauvilliers Y., Baumann C.R., Carlander B., Bischof M., Blatter T., Lecendreux M., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003, 74:1667-1673.
26. Heier M.S., Evsiukova T., Vilming S., Gjerstad M.D., Schrader H., Gautvik K.M. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007, 30:969-973.
27. Knudsen S., Jennum P.J., Alving J., Sheikh S.P., Gammeltoft S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 2010, 33:169-176.
28. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol (Chicago) 2002, 59:1553-1562.
29. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci 2001, 98:9965-9970.
30. Kodama T., Kimura M. Arousal effects of orexin-A correlate with GLU release from the locus coeruleus in rats. Peptides 2002, 23:1673-1681.
31. Scammell T.E. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003, 53:154-166.
32. Mochizuki T., Crocker A., McCormack S., Yanagisawa M., Sakurai T., Scammell T.E. Behavioral state instability in orexin knock-out mice. J Neurosci 2004, 24:6291-6300.
33. Saper C.B., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001, 24:726-731.
34. Baier P.C., Hallschmid M., Seeck-Hirschner M., Weinhold S.L., Burkert S., Diessner N., et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med Rev 2011, 12:941-946.
35. Herscovitch J., Broughton R. Sensitivity of the stanford sleepiness scale to the effects of cumulative partial sleep deprivation and recovery oversleeping. Sleep 1981, 4:83-91.
36. Hoddes E., Dement W.C., Zarcone V.P. The development and use of the Standford sleepiness scale (SSS). Psychophysiology 1973, 10:431-436.
37. Horne J.A., Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 1976, 4:97-110.
38. Hublin C., Kaprio J., Partinen M., Koskenvuo M., Heikkila K. The Ullanlinna narcolepsy scale: validation of a measure of symptoms in the narcoleptic syndrome. J Sleep Res 1994, 3:52-59.
39. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
40. Doghramji K., Mitler M.M., Sangal R.B., Shapiro C., Taylor S., Walsleben J., et al. A normative study of the maintenance of wakefulness test (MWT). Electroen Clin Neuro 1997, 103:554-562.
41. Thorpy M.J. The clinical use of the multiple sleep latency test. The standards of practice committee of the American sleep disorders association. Sleep 1992, 15:268-276.
42. Iber C., Ancoli-Israel S., Chesson A., Quan S.F. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications 2007, American Academy of Sleep Medicine, Illinois, Westchester. 1st ed.
43. Weeß H-G., Sauter C., Geisler P., Böhning W., Wilhelm B., Rotte M., et al. Vigilance, tendency to fall asleep, sustained attention, tiredness, sleepiness diagnostic tools for the measurement of sleepiness related processes and their criteria of quality. Somnologie 2000, 4:20-38.
44. Kummangal B.A., Kumar D., Mallick H.N. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behav Brain Res 2013, 237:59-62.
45. Baier P.C., Weinhold S.L., Huth V., Gottwald B., Ferstl R., Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin-1). Brain 2008, 131:2734-2741.
46. Deadwyler S.A., Porrino L., Siegel J.M., Hampson R.E. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247.
47. John J., Wu M.F., Siegel J.M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res 2000, 3:23-28.
48. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002, 5:514-516.
49. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliver Rev 2012, 64:614-628.
50. Fujiki N., Yoshida Y., Ripley B., Mignot E., Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26:953-959.
51. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009, 98:2501-2515.
52. Hanson L.R., Martinez P.M., Mignot E., Kamsheh L., Taheri S., Frey W.H. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv 2004, 4.
53. Mattarozzi K., Bellucci C., Campi C., Cipolli C., Ferri R., Franceschini C., et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. Sleep Med Rev 2008, 9:425-433.